Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May;45(5):2321-2324.
doi: 10.1007/s10072-024-07336-8. Epub 2024 Jan 25.

Using an expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in U.S. and UK

Ali Abbasi  1 , Henrik Fryk  2 , Jan Rudnik  2 , Richard White  3 , Mark Vanderkelen  4 , Anna Scowcroft  2 , Kerina Bonar  2
Affiliations

Using an expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in U.S. and UK

Ali Abbasi et al. Neurol Sci. 2024 May.

Abstract

Background: There is an increasing need to better understand the burden of amyotrophic lateral sclerosis (ALS) using real-world data (RWD). However, identifying ALS cases using RWD presents several challenges due to the rarity of ALS and the differences in database coding systems.

Methods: MarketScan claims, and the UK Clinical Practice Research Datalink (CPRD) databases were searched for diagnosis codes of ALS or MND, the only drugs approved for treating ALS (riluzole and edaravone) and clinical visits with 12-month enrolment prior to 1 January 2011. The main algorithm required ≥ 1 ALS diagnosis code together with prescriptions or clinical visits. We expanded the existing algorithm to identify unspecific (possible) ALS group that had codes for motor neuron disease (MND) and the ALS drugs. The study period was from 1 January 2011 until 31 December 2020.

Results: We identified 16,246 patients with ≥ 1 ALS code in Marketscan (denominator n = 85,279,619), yet only 184 were found in the UK CPRD (denominator n = 21,318,589). Using the main algorithm 9,433 ALS patients were included in MarketScan, with a prevalence ranged between 4.5 per 100,000 in 2019 and 6.2 in 2015. In MarketScan, 3,658 (4.3 per 100,000) had ≥ 1 MND code and the ALS drug codes (possible cases). In CPRD, 47.9% of 2,785 patients with ≥ 1 MND code had a prescription for riluzole (6.3 per 100,000), regarded as possible ALS cases.

Conclusions: The expanded algorithm enabled the identification of a large population with ALS, or possible ALS, and the estimation of ALS prevalence in MarketScan and CPRD.

Keywords: Algorithm; Amyotrophic lateral sclerosis; Epidemiology; U.S. Claims; UK primary care.

PubMed Disclaimer

References

    1. Feldman EL, Goutman SA, Petri S et al (2022) Amyotrophic lateral sclerosis. Lancet 400:1363–1380. https://doi.org/10.1016/s0140-6736(22)01272-7 - DOI - PubMed - PMC
    1. Arthur KC, Calvo A, Price TR et al (2016) Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun 7:12408. https://doi.org/10.1038/ncomms12408 - DOI - PubMed - PMC
    1. Mehta P, Kaye W, Raymond J et al (2018) Prevalence of amyotrophic lateral sclerosis - United States, 2014. MMWR Morb Mortal Wkly Rep 67:216–218. https://doi.org/10.15585/mmwr.mm6707a3
    1. Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377:162–172. https://doi.org/10.1056/NEJMra1603471 - DOI - PubMed
    1. [Anonymous] (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18:459–480. https://doi.org/10.1016/s1474-4422(18)30499-x

LinkOut - more resources